Supernus Pharmaceuticals
ISIN US8684591089
|WKN A1JX3U
Overview
Description
Supernus Pharmaceuticals, Inc. développe et commercialise des produits pour le traitement des maladies du système nerveux central. Elle propose les produits Trokendi XR, Oxtellar XR, APOKYN, XADAGO et MYOBLOC. La société a été fondée par Jack A. Khattar le 30 mars 2005 et son siège social se trouve à Rockville, MD.
Santé Produits biopharmaceutiques Produits biopharmaceutiques systémiques États-Unis
Financials
Key metrics
| Market capitalisation, EUR | 1 551,05 M |
| EPS, EUR | 1,22 |
| P/B ratio | 1,67 |
| P/E ratio | 23,54 |
| Dividend yield | 0,00% |
Income statement (2024)
| Revenue, EUR | 611,83 M |
| Net income, EUR | 68,29 M |
| Profit margin | 11,16% |
What ETF is Supernus Pharmaceuticals in?
There are 28 ETFs which contain Supernus Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Supernus Pharmaceuticals is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
